Beta-Blockers Library

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

Beta-Blockers DMPK and Bioanalytical Services

Beta-blocker bioanalysis is defined by CYP2D6 — but not uniformly. Propranolol, metoprolol, and carvedilol are CYP2D6 substrates whose metabolic rate varies 5- to 10-fold across poor, extensive, and ultra-rapid metabolizer genotypes. Bisoprolol balances CYP2D6 and CYP3A4, partially buffering CYP2D6 variability. Atenolol is not CYP-metabolized — it clears renally as unchanged parent. A single pooled-microsome incubation that works for metoprolol (extensive metabolizer genotype) will misrepresent carvedilol clearance in a poor-metabolizer donor, and has no analytical relevance to atenolol at all.

Creative Proteomics provides beta-blocker-focused DMPK workflows spanning CYP2D6 polymorphism-aware metabolism and MetID, CYP2D6-genotyped microsome and hepatocyte models, non-metabolized compound disposition and excretion analysis, and custom multi-beta-blocker panels.

Browse Beta-Blocker Drug Index Request Custom Beta-Blocker Method Support

CYP2D6 Polymorphism Drives Metabolic VariabilityCYP2D6 genotype determines metabolic rate for propranolol, metoprolol, and carvedilol. Pooled microsomes mask 5- to 10-fold inter-genotype differences.

Atenolol: The Non-Metabolized OutlierAtenolol is not a CYP substrate. Renal excretion of unchanged parent is the primary clearance route — a metabolic workup adds nothing.

Bisoprolol: Dual CYP2D6/CYP3A4 BufferBalanced metabolism across two CYP pathways reduces genotype-driven variability compared to single-CYP2D6 beta-blockers.

Beta-Blocker CYP2D6 Genotype Risks DMPK Strategy Map

⚡

CYP2D6 Polymorphism ClassificationPropranolol, metoprolol, and carvedilol are CYP2D6 substrates with 5- to 10-fold genotype-driven variability. Bisoprolol balances CYP3A4 and CYP2D6. Atenolol is not CYP-metabolized — three distinct analytical identities.

🧬

CYP2D6-Genotyped Metabolism & MetIDPropranolol (CYP2D6/CYP1A2), metoprolol (CYP2D6), carvedilol (CYP2D6/CYP1A2/CYP2C9) require separate genotyped microsome/hepatocyte incubation arms.

📊

Non-Metabolized Compound ExcretionAtenolol clears renally as unchanged parent. No CYP incubation needed — excretion and distribution are the primary analytical endpoints.

🔬

Dual-CYP & Multi-CYP Pathway ProfilingBisoprolol (CYP3A4/CYP2D6) and carvedilol (CYP2D6/CYP1A2/CYP2C9) require multi-isoform incubation with selective inhibition controls.

Beta-blocker-specific CYP2D6 genotype triage.Creative Proteomics determines CYP2D6 genotype sensitivity, single or multi-CYP status, and non-metabolized classification before method development — because a pooled-microsome incubation cannot distinguish poor metabolizers from ultra-rapid metabolizers, and has no relevance to non-metabolized compounds.

Beta-Blocker Drug Index

Find the Beta-Blocker Compound Behind the Study

Beta-blocker studies split by a key analytical question: is the compound a CYP2D6 substrate with genotype-sensitive metabolism, a dual-CYP substrate with buffered variability, or a non-metabolized compound requiring excretion analysis? Use the index to classify the metabolic status and route the workflow accordingly. The drug panels are intentionally concise so detailed compound monographs can be added separately.

A–Z anchors

Filter by study tagsSelect a field to reveal its tags. Multiple tags work together as narrowing filters, so the drug index shows only beta-blockers matching all selected values.

5 entries · Page 1 of 3

Analytical Pain Points

What Drives Assay Failure in Beta-Blocker Studies?

Beta-blockers fail analytically when CYP2D6 genotype is ignored — the same dose of metoprolol produces radically different plasma concentrations in a poor metabolizer vs an ultra-rapid metabolizer. Atenolol fails when it is pushed through a metabolic workup it doesn’t need. The core issue is whether the lab accounts for CYP2D6 polymorphism and recognizes the non-CYP outlier.

CYP2D6 Polymorphism Makes Pooled Microsomes Misleading

Propranolol, metoprolol, and carvedilol are CYP2D6 substrates. Pooled microsomes average across genotypes and obscure the 5- to 10-fold metabolic rate differences between poor, extensive, and ultra-rapid CYP2D6 metabolizers — producing clearance data that doesn’t represent any real population.

Our responseCYP2D6-genotyped microsome and hepatocyte models with isoform-specific activity verification and separate incubation arms per genotype.

Metabolite Identification →

Atenolol Requires Excretion Workflows, Not Metabolic Incubation

Atenolol is not a CYP substrate. Running it through β-NADPH-supplemented microsome incubation wastes time and produces no meaningful metabolite data. The analytical question is renal excretion and tissue distribution of unchanged parent.

Our responseNon-metabolized compound bioanalysis with plasma, urine, and tissue-sample quantification focused on excretion and distribution endpoints.

Complex Biological Matrices →

Carvedilol’s Multi-CYP Profile Amplifies Genotype Complexity

Carvedilol is metabolized by CYP2D6, CYP1A2, and CYP2C9. A CYP2D6-genotyped model alone captures only one of three metabolic pathways, leaving CYP2C9 and CYP1A2 contributions unmeasured.

Our responseMulti-CYP incubation panels covering CYP2D6, CYP1A2, and CYP2C9 simultaneously for carvedilol with isoform-selective inhibition controls.

Phase I & II Metabolite Characterization →

Bisoprolol’s Dual-Pathway Buffer Masks Enzyme-Specific Issues

Bisoprolol is metabolized by both CYP3A4 and CYP2D6. Dual-pathway clearance reduces genotype sensitivity — but also means that if one pathway is inhibited (e.g., CYP3A4 by a co-administered drug), the other carries the full clearance burden, which single-isoform incubation won’t detect.

Our responseDual-CYP3A4/CYP2D6 incubation with selective inhibition controls to assess pathway contribution and single-pathway failure risk.

Metabolite Identification →

Multi-Beta-Blocker Panels Must Separate CYP Substrates from Non-Metabolized Compounds

A panel containing CYP2D6 substrates (propranolol, metoprolol, carvedilol), a dual-CYP substrate (bisoprolol), and a non-metabolized compound (atenolol) requires CYP-genotyped incubation for metabolic substrates alongside excretion-focused analysis for atenolol — two analytical strategies in one study.

Our responseCustom multi-beta-blocker LC-MS/MS panels with CYP2D6-genotyped incubation arms for metabolic substrates and excretion-focused quantification for non-metabolized atenolol.

Custom Panels →

Focused Service Paths

Four Practical Routes for Beta-Blocker Studies

Beta-blocker workflows should be selected according to metabolic status: CYP2D6-genotyped metabolism and MetID for CYP2D6 substrates; multi-CYP incubation for carvedilol; dual-CYP3A4/CYP2D6 profiling for bisoprolol; or excretion-focused analysis for non-metabolized atenolol.

CYP2D6 Polymorphism-Aware Metabolism & MetID

For propranolol, metoprolol, and other CYP2D6 substrates requiring genotype-sensitive Phase I metabolism profiling in microsome and hepatocyte models.

CYP2D6-genotyped microsome/hepatocyte incubation
Poor, extensive, and ultra-rapid metabolizer arms
Phase I metabolite profiling
Genotype-stratified clearance data

Metabolite Identification →

Non-Metabolized Compound Excretion & Distribution

For atenolol and other non-CYP-metabolized beta-blockers where renal excretion and tissue distribution are the primary endpoints.

Plasma and urine unchanged-parent quantification
Renal excretion profiling
Tissue distribution analysis
No-CYP workflow validation

Complex Biological Matrices →

Multi-CYP & Dual-Pathway Metabolic Profiling

For carvedilol (CYP2D6/1A2/2C9) and bisoprolol (CYP3A4/2D6) — multi-isoform incubation with selective inhibition to assess pathway contribution and single-pathway failure risk.

Multi-CYP incubation panels
Isoform-selective inhibition controls
Pathway contribution assessment

Phase I & II Metabolite Characterization →

Custom Multi-Beta-Blocker Panel Development

For studies combining CYP2D6 substrates, dual-CYP substrates, and non-metabolized compounds in one validated method.

CYP-genotyped incubation for metabolic substrates
Excretion-focused quantification for non-metabolized
Panel-level genotype and matrix compatibility

Custom Multi-Analyte Drug Panels →

Project Inquiry

Need Support for a Novel or Unlisted Beta-Blocker?

If you are working with a CYP2D6 substrate requiring genotype-sensitive MetID, a multi-CYP compound needing isoform-specific profiling, a non-metabolized beta-blocker requiring excretion analysis, or a mixed-status panel, standard pooled-microsome methods may not capture genotype-driven variability.

Creative Proteomics designs custom beta-blocker workflows by defining CYP2D6 genotype sensitivity, single or multi-CYP status, non-metabolized compound classification, biological matrix, and panel composition before method development.

Target beta-blocker

CYP2D6 genotype sensitivity

Single or multi-CYP metabolism

Non-metabolized or metabolic

Excretion / distribution focus

Panel requirements

Beta-Blockers DMPK and Bioanalytical Services

Find the Beta-Blocker Compound Behind the Study

What Drives Assay Failure in Beta-Blocker Studies?

CYP2D6 Polymorphism Makes Pooled Microsomes Misleading

Atenolol Requires Excretion Workflows, Not Metabolic Incubation

Carvedilol’s Multi-CYP Profile Amplifies Genotype Complexity

Bisoprolol’s Dual-Pathway Buffer Masks Enzyme-Specific Issues

Multi-Beta-Blocker Panels Must Separate CYP Substrates from Non-Metabolized Compounds

Four Practical Routes for Beta-Blocker Studies

CYP2D6 Polymorphism-Aware Metabolism & MetID

Non-Metabolized Compound Excretion & Distribution

Multi-CYP & Dual-Pathway Metabolic Profiling

Custom Multi-Beta-Blocker Panel Development

Need Support for a Novel or Unlisted Beta-Blocker?

Ready to Quantify Your Lead Compound or Metabolite?